Chimerix Inc. (www.chimerix-inc.com), a biotech company with offices in San Diego and Durham, has raised $11 million from a private placement of Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the round with additional funding from founding investors Sanderling Ventures and Asset Management Company.
This financing will help the company advance its current therapeutic programs and broaden the application of our proprietary technology to new therapeutic indications. The funds will allow Chimerix to acquire additional developmental resources for advancing the company's lead antiviral agent (CMX001) for treatment of smallpox infection toward clinical trials. The financing will complement a $36.1 million grant from the National Institutes of Health awarded to Chimerix.